Similarities and differences in clinical and pathologic features of inflammatory bowel disease-associated colorectal cancer in China and Canada
10.1097/CM9.0000000000000525
- Author:
Ji LI
1
;
Wei-Xun ZHOU
2
;
Shuang LIU
1
;
Wei-Yang ZHENG
1
;
Ya-Nan WANG
1
;
Jing-Nan LI
1
;
Jose Gp FERRAZ
3
;
Jia-Ming QIAN
1
;
Xian-Yong GUI
4
Author Information
1. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
2. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
3. Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
4. Department of Pathology and Laboratory Medicine, University of Calgary Cummings School of Medicine, and Calgary Laboratory Services, Calgary, Canada; Department of Pathology, University of Washington School of Medicine, Seattle, USA
- Publication Type:Journal Article
- Keywords:
Colitis-associated colorectal cancer;
Comparative study;
Crohn’s disease;
Inflammatory bowel disease;
Ulcerative colitis
- From:
Chinese Medical Journal
2019;132(22):2664-2669
- CountryChina
- Language:English
-
Abstract:
Background:Colorectal cancer (CRC) has become one of the major life-threatening complications in patients with inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD). This study aimed to explore the clinicalpathologic similarities and differences in the IBD-associated CRC (IBD-CRC) between patients in China and Canada.
Methods:Data of 78 patients with IBD-CRC retrospectively retrieved from two representative medical institutions in Beijing (China) and Calgary (Canada) over the same past 13 years, including 25 (22 UC-associated and three CD-associated) from Beijing group and 53 (32 UC-associated and 21 CD-associated) from Calgary group, were compared with regards to their clinical and pathologic characteristics.
Results:Several known features of IBD-CRC were seen in both groups, including long duration and large extent of colitis, active inflammation background, multifocal lesions, and advanced tumor-node-metastasis stage. Beijing group showed a significantly higher percentage of UC (88.0% vs. 60.4%, P = 0.018), younger age at diagnosis of CRC (48.6 ± 12.8 years vs. 61.6 ± 14.7 years, P < 0.001), lower ratio of mucinous adenocarcinoma (7.1% vs. 42.4%, P = 0.001) compared with Calgary group. None of the Beijing group had concurrent primary sclerosing cholangitis, while 5.7% of Calgary group did. Surveillance colonoscopy favored the detection rate of precancerous lesions (41.4% vs.17.0%, P = 0.002).
Conclusions:As compared with patients from the Calgary group, the IBD-CRC patients in Beijing group were younger, less CD-associated and had less mucinous features, otherwise they were similar in many common features.
